187 related articles for article (PubMed ID: 26642646)
1. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].
Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre
Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646
[TBL] [Abstract][Full Text] [Related]
2. [The patients' cost of the montelukast therapy due to the generic substitution].
Répásy B; Endrei D; Zemplényi A; Ágoston I; Boncz I
Orv Hetil; 2018 Apr; 159(17):682-687. PubMed ID: 29681174
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
Spinks J; Chen G; Donovan L
Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
[TBL] [Abstract][Full Text] [Related]
5. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
6. The long-term effect of generic price competition on the Hungarian statin market.
Répásy B; Gazsó T; Elmer D; Pónusz-Kovács D; Kajos FL; Csákvári T; Kovács B; Boncz I
BMC Health Serv Res; 2023 May; 23(1):447. PubMed ID: 37147682
[TBL] [Abstract][Full Text] [Related]
7. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
8. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
9. [Health insurance pharmaceutical expenditures in Hungary].
Eisingerné Balassa B; Csákvári T; Ágoston I
Orv Hetil; 2019 Feb; 160(Suppl 1):49-54. PubMed ID: 30724598
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
11. Some drugs more equal than others: pseudo-generics and commercial practice.
Probyn AJ
Aust Health Rev; 2004 Nov; 28(2):207-17. PubMed ID: 15527401
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of annual health insurance reimbursement for oncology drugs in Hungary].
Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
Magy Onkol; 2010 Dec; 54(4):283-8. PubMed ID: 21163758
[TBL] [Abstract][Full Text] [Related]
13. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
14. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
15. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
Hornyák L; Nagy Z; Ilku L; Tálos Z; Endrei D; Ágoston I; Csákvári T; Danku N; Répásy B; Boncz I
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):725-731. PubMed ID: 30763134
[No Abstract] [Full Text] [Related]
16. Pricing of drugs with heterogeneous health insurance coverage.
Ferrara I; Missios P
J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
[TBL] [Abstract][Full Text] [Related]
17. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
18. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
19. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
20. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]